These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27725591)

  • 1. [Treatment of acute myeloid leukemia under relapsed/refractory conditions or in older adults].
    Yamauchi T
    Rinsho Ketsueki; 2016; 57(10):1934-1943. PubMed ID: 27725591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
    Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
    Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome].
    Zhu CY; Yang H; Niu JH; Zhang Q; Xie XL; Wang LJ; Zhu HY; Yao ZL; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):950-6. PubMed ID: 25130809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
    Ferguson P; Hills RK; Grech A; Betteridge S; Kjeldsen L; Dennis M; Vyas P; Goldstone AH; Milligan D; Clark RE; Russell NH; Craddock C;
    Haematologica; 2016 Nov; 101(11):1351-1358. PubMed ID: 27540133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of relapsed or refractory acute myeloid leukemia].
    Kobayashi H
    Rinsho Ketsueki; 2017; 58(10):1895-1904. PubMed ID: 28978830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
    O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
    Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
    Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?
    Finn LE; Foran JM
    Curr Opin Hematol; 2016 Mar; 23(2):95-101. PubMed ID: 26825695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
    Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia.
    Stone RM; O'Donnell MR; Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.